Skip to main content
Article thumbnail
Location of Repository

Reducing Glycosphingolipid Content in Adipose Tissue of Obese Mice Restores Insulin Sensitivity, Adipogenesis and Reduces Inflammation

By Marco van Eijk, Jan Aten, Nora Bijl, Roelof Ottenhoff, Cindy P. A. A. van Roomen, Peter F. Dubbelhuis, Ingar Seeman, Karen Ghauharali-van der Vlugt, Hermen S. Overkleeft, Cynthia Arbeeny, Albert K. Groen and Johannes M. F. G. Aerts


Adipose tissue is a critical mediator in obesity-induced insulin resistance. Previously we have demonstrated that pharmacological lowering of glycosphingolipids and subsequently GM3 by using the iminosugar AMP-DNM, strikingly improves glycemic control. Here we studied the effects of AMP-DNM on adipose tissue function and inflammation in detail to provide an explanation for the observed improved glucose homeostasis. Leptin-deficient obese (LepOb) mice were fed AMP-DNM and its effects on insulin signalling, adipogenesis and inflammation were monitored in fat tissue. We show that reduction of glycosphingolipid biosynthesis in adipose tissue of LepOb mice restores insulin signalling in isolated ex vivo insulin-stimulated adipocytes. We observed improved adipogenesis as the number of larger adipocytes was reduced and expression of genes like peroxisome proliferator-activated receptor (PPAR) γ, insulin responsive glucose transporter (GLUT)-4 and adipsin increased. In addition, we found that adiponectin gene expression and protein were increased by AMP-DNM. As a consequence of this improved function of fat tissue we observed less inflammation, which was characterized by reduced numbers of adipose tissue macrophages (crown-like structures) and reduced levels of the macrophage chemo attractants monocyte-chemoattractant protein-1 (Mcp-1/Ccl2) and osteopontin (OPN). In conclusion, pharmacological lowering of glycosphingolipids by inhibition of glucosylceramide biosynthesis improves adipocyte function and as a consequence reduces inflammation in adipose tissue of obese animals

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2001). A new mathematical model for relative quantification in realtime RT-PCR.
  2. (1957). A simple method for the isolation and purification of total lipides from animal tissues.
  3. (2007). A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways.
  4. (2008). Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals.
  5. (2006). Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes.
  6. (2005). Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans.
  7. (2006). Adipocyte differentiation from the inside out.
  8. (2008). Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes.
  9. (2008). Adipogenic capacity and the susceptibility to type 2 diabetes and metabolic syndrome.
  10. (2006). Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome.
  11. (2009). Adiponectin reduces lipid accumulation in macrophage foam cells.
  12. (2006). Adiponectin: a key adipocytokine in metabolic syndrome.
  13. (2005). Adipose development: from stem cell to adipocyte.
  14. (2007). Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity.
  15. (2004). Analysis of fluorescently labeled glycosphingolipid-derived oligosaccharides following ceramide glycanase digestion and anthranilic acid labeling.
  16. (2003). Biosynthesis and degradation of mammalian glycosphingolipids.
  17. (2006). CCR2 modulates inflammatory and metabolic effects of high-fat feeding.
  18. (2006). Ceramides in insulin resistance and lipotoxicity.
  19. (2003). Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance.
  20. (1981). DEAE-silica gel and DEAE-controlled porous glass as ion exchangers for the isolation of glycolipids.
  21. (2007). Dissociation of the insulin receptor and caveolin-1 complex by ganglioside GM3 in the state of insulin resistance.
  22. (2003). Enhanced insulin sensitivity in mice lacking ganglioside GM3.
  23. (2002). Ganglioside GM3 participates in the pathological conditions of insulin resistance.
  24. (1998). Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase.
  25. (2007). HPLC for simultaneous quantification of total ceramide, glucosylceramide, and ceramide trihexoside concentrations in plasma.
  26. (2006). Inflamed fat: what starts the fire?
  27. (2008). Inflammation and insulin resistance.
  28. (2006). Inflammation and metabolic disorders.
  29. (2007). Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes.
  30. (2007). Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance.
  31. (2004). Inhibition of glycolipid biosynthesis by N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin protects against the inflammatory response in hapten-induced colitis.
  32. (2002). Lipoapoptosis: its mechanism and its diseases.
  33. (2006). MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity.
  34. (2003). Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome.
  35. (2007). Naaz A
  36. (1999). Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin.
  37. (2007). Obesity induces a phenotypic switch in adipose tissue macrophage polarization.
  38. (2003). Obesity is associated with macrophage accumulation in adipose tissue.
  39. (2007). Obesity-associated improvements in metabolic profile through expansion of adipose tissue.
  40. (2003). Obesity-induced inflammatory changes in adipose tissue.
  41. (2007). Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice.
  42. (2006). Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance.
  43. (2001). Peroxisome proliferatoractivated receptor gamma and metabolic disease.
  44. (2007). Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity.
  45. (2008). Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes.
  46. (2007). Plasma osteopontin levels and expression in adipose tissue are increased in obesity.
  47. (2008). Principles of bioactive lipid signalling: lessons from sphingolipids.
  48. (2008). Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease.
  49. (2005). The adipose organ
  50. (1998). The metabolically obese, normal-weight individual revisited.
  51. (2008). The secretory function of adipocytes in the physiology of white adipose tissue.
  52. (2006). TLR4 links innate immunity and fatty acid-induced insulin resistance.
  53. (2005). TNFalphainduced insulin resistance in adipocytes as a membrane microdomain disorder: involvement of ganglioside GM3.
  54. (1995). Transcriptional regulation of gene expression during adipocyte differentiation.
  55. Vidal-Puig AJ (2007) Adipose tissue expandability in the maintenance of metabolic homeostasis.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.